Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry
- 1 August 2015
- journal article
- research article
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 21 (8) , 871-876
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Duodopa® treatment for advanced Parkinson's disease: A review of efficacy and safetyParkinsonism & Related Disorders, 2012
- Practical Guidance on How to Handle Levodopa/Carbidopa Intestinal Gel Therapy of Advanced PD in a Movement Disorder ClinicThe Open Neurology Journal, 2012
- Levodopa–carbidopa intestinal gel for treatment of advanced Parkinson’s diseaseCurrent Medical Research and Opinion, 2011
- Systematic review of levodopa dose equivalency reporting in Parkinson's diseaseMovement Disorders, 2010
- Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's diseaseMovement Disorders, 2009
- Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of lifeMovement Disorders, 2009
- Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcomeMovement Disorders, 2007
- Long-term 24-hour duodenal infusion of levodopa: Outcome and dose requirementsNeurology, 2005
- Dyskinesias and motor fluctuations in Parkinson's diseaseBrain, 2000
- Pathogenesis of dyskinesias in parkinson's diseaseAnnals of Neurology, 1989